SP
MRNA icon

Symmetry Partners’s Moderna MRNA Stock Holding History

Symmetry Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,474
Closed -$413K – 351
2024
Q2 		$413K Hold
3,474
– – 0.02% 332
2024
Q1 		$370K Hold
3,474
– – 0.03% 364
2023
Q4 		$343K Sell
3,474
-637
-15% -$53.6K 0.02% 358
2023
Q3 		$425K Sell
4,111
-987
-19% -$110K 0.02% 349
2023
Q2 		$619K Sell
5,098
-2,376
-32% -$317K 0.03% 273
2023
Q1 		$1.15M Buy
7,474
+760
+11% +$125K 0.06% 162
2022
Q4 		$1.21M Hold
6,714
– – 0.07% 150
2022
Q3 		$794K Buy
6,714
+2,654
+65% +$403K 0.05% 205
2022
Q2 		$580K Sell
4,060
-4,125
-50% -$590K 0.04% 276
2022
Q1 		$1.41M Sell
8,185
-1,266
-13% -$213K 0.09% 137
2021
Q4 		$2.4M Buy
9,451
+280
+3% +$81.9K 0.15% 84
2021
Q3 		$3.05M Hold
9,171
– – 0.2% 67
2021
Q2 		$2.15M Buy
9,171
+6,350
+225% +$1.13M 0.14% 94
2021
Q1 		$369K Sell
2,821
-210
-7% -$30.4K 0.03% 503
2020
Q4 		$317K Buy
+3,031
New +$307K 0.02% 511

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Symmetry Partners's MRNA Position: Q3 2024 in Review

Symmetry Partners sold out of Moderna (MRNA) in Q3 2024, closing a stake of 3,474 shares — an estimated $413K sold.

Symmetry Partners first reported a position in MRNA in Q4 2020 and held it in 15 quarters. The position peaked at $3.05M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Symmetry Partners reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Symmetry Partners sold 3,474 Moderna shares in Q3 2024, an estimated $413K.
  • Symmetry Partners first reported a position in Moderna in Q4 2020 and held it in 15 quarters.
  • Symmetry Partners's Moderna position peaked at $3.05M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Symmetry Partners's 13F filing for Q3 2024, filed 29 Oct 2024.